USAL – University of Salamanca

University of Salamanca is one of the oldest Universities in Europe, founded in 1218 and initially dedicated to the study of medicine, humanities, theology and law, has today become a modern European University, open to the culture of practically every branch of teaching. Currently, the University of Salamanca deal studies of the first and second cycle to almost 28.000 pupils, to whom they add near 3.000 pupils of Doctorate and Master with more than three thousand researchers, who make up 70 departments, 26 Faculties and Schools, 18 institutes and other research units belonging to the social, biomedical, human, experimental and formal sciences, stands out as one of the main public research organizations in Spain.

The University of Salamanca puts its support and scientific and technologic consulting resources -a network of institutes, of our own or contracted, an Office for European Research Projects, an Office for the transference of technology (OTRI) and several Central Services- within the reach of the scientific community, the institutions and the industry. The University of Salamanca has participated and is participating in several European projects under the subsequent RTD European Framework Programmes (I to VII) and other European Programmes / Actions: ERASMUS, SOCRATES, LEONARDO, EQUAL, Community Action Programme “Cancer and other communicable diseases”… acting through several roles: coordinator, contractor, associated contractor, member, host institution, therefore, having experience in the development and management of more than 100 European Projects. The University of Salamanca participated in 53 community actions financed under the VI Framework Programme: Integrated Project, Network of Excellence, Specific Support Actions and Marie Curie Actions. At present, we are participating in 30 projects financed under the FP7. This project shall be carried out by the University of Salamanca through the Neuroscience Institute of Castilla y León (INCyL), devoted to the study of the nervous system and its pathologies. Its main areas are CNS diseases and clinical studies, Cellular and Molecular Neurobiology, Neurobiology Systems, and regenerative medicine

Juan Carlos Arevalo

Ph.D.
Associate Professor
Universidad de Salamanca – Department of Cellular Biology and Pathology
arevalojc@usal.es

Dr. Juan Carlos Arévalo will be project leader WP and will contribute to WP1, WP4, and WP5. Dr. Arévalo has 16 years of experience working on the neurotrophin field, 4 years as a graduate student (University of Salamanca), 7 years as a postdoc (Skirball Institute, New York) and 5 years as a principal investigator (University of Salamanca).

Actually, Dr. Arévalo holds a permanent position as Associate Professor at the University of Salamanca and he has developed a mouse model that has an impaired ubiquitination of the NGF receptor TrkA that will be used in this project.

Laura Calvo Enrique

lau@usal.es

Laura Calvo has a degree in Pharmacy and Biochemistry by the University of Salamanca (Spain) and a Master in “Neuroscience” at the Institute of Neuroscience (INCyL) in Salamanca, where she got her PhD under the supervision of Juan Carlos Arévalo. At the moment, she is performing functional and behavioural experiments using TrkAP782S knock-in mice as a model for neuropathic pain and osteoarthrosis.

Publications:

• Yu T.*, Calvo L.*, Anta B., López-Benito S., López-Bellido R., Vicente-García C., Tessarollo L., Rodríguez R.E. and Arévalo J.C. 2014. In vivo regulation of NGF-mediated functions by nedd4-2 ubiquitination of TrkA. J. Neurosci. 34: 6098-6106. *Equal contribution.
• Yu T., Calvo L., Anta B., López-Benito S., Southon E., Chao M.V, Tessarollo L and Arévalo J.C. 2011. Regulation of trafficking of activated TrkA is critical for NGF-mediated functions. Traffic. 12: 521-34

Carlos Martín Rodríguez

chalymr@usal.es

Carlos Martín has a degree in Biology and a Master in “Neuroscience” at the Institute of Neuroscience (INCyL) in Salamanca. He is currently carrying out his Doctoral Thesis investigating the role of different deubiquitinases on Trk neurotrophin receptors.